Unknown

Dataset Information

0

Pathophysiology of hypophosphatasia and the potential role of asfotase alfa.


ABSTRACT: Hypophosphatasia (HPP) is an inherited systemic bone disease that is characterized by bone hypomineralization. HPP is classified into six forms according to the age of onset and severity as perinatal (lethal), perinatal benign, infantile, childhood, adult, and odontohypophosphatasia. The causative gene of the disease is the ALPL gene that encodes tissue-nonspecific alkaline phosphatase (TNAP). TNAP is expressed ubiquitously, and its physiological role is apparent in bone mineralization. A defect in bone mineralization can manifest in several ways, including rickets or osteomalacia in HPP patients. Patients with severe forms suffer from respiratory failure because of hypoplastic chest, which is the main cause of death. They sometimes present with seizures due to a defect in vitamin B6 metabolism resulting from the lack of alkaline phosphatase activity in neuronal cells, which is also lethal. Patients with a mild form of the disease exhibit rickets or osteomalacia and a functional defect of exercise. Odontohypophosphatasia shows only dental manifestations. To date, 302 mutations in the ALPL gene have been reported, mainly single-nucleotide substitutions, and the relationships between phenotype and genotype have been partially elucidated. An established treatment for HPP was not available until the recent development of enzyme replacement therapy. The first successful enzyme replacement therapy in model mice using a modified human TNAP protein (asfotase alfa) was reported in 2008, and subsequently success in patients with severe form of the disease was reported in 2012. In 2015, asfotase alfa was approved in Japan in July, followed by in the EU and Canada in August, and then by the US Food and Drug Administration in the USA in October. It is expected that therapy with asfotase alfa will drastically change treatments and prognosis of HPP.

SUBMITTER: Orimo H 

PROVIDER: S-EPMC4876073 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pathophysiology of hypophosphatasia and the potential role of asfotase alfa.

Orimo Hideo H  

Therapeutics and clinical risk management 20160517


Hypophosphatasia (HPP) is an inherited systemic bone disease that is characterized by bone hypomineralization. HPP is classified into six forms according to the age of onset and severity as perinatal (lethal), perinatal benign, infantile, childhood, adult, and odontohypophosphatasia. The causative gene of the disease is the ALPL gene that encodes tissue-nonspecific alkaline phosphatase (TNAP). TNAP is expressed ubiquitously, and its physiological role is apparent in bone mineralization. A defect  ...[more]

Similar Datasets

| S-EPMC5033855 | biostudies-literature
| S-EPMC8100395 | biostudies-literature
| S-EPMC8608777 | biostudies-literature
| S-EPMC7284058 | biostudies-literature
| S-EPMC6161731 | biostudies-literature
| S-EPMC4605638 | biostudies-literature
| S-EPMC4346954 | biostudies-other
| S-EPMC2164941 | biostudies-literature